Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) R&D In Process (2019 - 2026)

Neurocrine Biosciences filings provide 6 years of R&D In Process readings, the most recent being $17.0 million for Q4 2025.

  • On a quarterly basis, R&D In Process rose 466.67% to $17.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.4 million, a 39.2% increase, with the full-year FY2025 number at $17.4 million, up 39.2% from a year prior.
  • R&D In Process hit $17.0 million in Q4 2025 for Neurocrine Biosciences, up from $300000.0 in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $143.9 million in Q1 2023 to a low of $100000.0 in Q1 2025.
  • Median R&D In Process over the past 4 years was $4.0 million (2021), compared with a mean of $27.9 million.
  • The widest YoY moves for R&D In Process: up 466.67% in 2025, down 98.33% in 2025.
  • Neurocrine Biosciences' R&D In Process stood at $100.3 million in 2021, then soared by 43.47% to $143.9 million in 2023, then tumbled by 97.92% to $3.0 million in 2024, then skyrocketed by 466.67% to $17.0 million in 2025.
  • The last three reported values for R&D In Process were $17.0 million (Q4 2025), $300000.0 (Q3 2025), and $100000.0 (Q1 2025) per Business Quant data.